Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis
Identifieur interne : 001F01 ( Main/Exploration ); précédent : 001F00; suivant : 001F02Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis
Auteurs : S. Bernatsky ; M. Hudson ; S. Suissa [Canada]Source :
- Rheumatology [ 1462-0324 ] ; 2005.
Abstract
Objective. To assess the risk of hospitalization for congestive heart failure (CHF) associated with the use of disease-modifying anti-rheumatic drugs (DMARDs) and other medications used in RA. Methods. We used a case–control design nested within an administrative database cohort of patients with rheumatoid arthritis (RA) who were dispensed a DMARD between September 1998 and December 2001. Subjects identified with a prior history of CHF were excluded. For each hospitalized case of CHF identified during follow-up, 10 controls matched on age and time were randomly selected from the cohort. Conditional logistic regression was used to estimate the rate ratio (RR) of hospitalizations for CHF associated with the current use of specific drugs, adjusted for sex and co-morbidity. Results. The cohort included 41 885 patients; 75% were women, with an average age at cohort entry of 51 yr. During follow-up, 520 hospitalizations for CHF occurred, for a rate of 10.1 per 1000 per year. The adjusted RR of CHF for current use of any DMARD was 0.7 (95% CI 0.6–0.9) relative to no current use. By DMARD category, there was evidence of a beneficial effect for both tumour necrosis factor-α antagonists (RR 0.5, 95% CI 0.2–0.9) and methotrexate monotherapy (RR 0.8, 95% CI 0.6–1.0). For non-DMARD medications, the rate of CHF was not clearly increased or decreased, except for COX-2 inhibitors. The data suggested an increased risk of CHF with rofecoxib (RR 1.3, 95% CI 1.0–3.1) and a decreased risk of CHF with celecoxib (RR 0.6, 95% CI 0.4, 1.0). Conclusions. The use of DMARDs was associated with a reduction in the risk of hospitalizations for CHF in this RA cohort. The increased risk with rofecoxib alongside a decreased risk with celecoxib suggests the absence of a class effect with respect to COX-II inhibitors for some types of cardiovascular morbidity.
Url:
DOI: 10.1093/rheumatology/keh610
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000252
- to stream Istex, to step Curation: 000252
- to stream Istex, to step Checkpoint: 000D51
- to stream Main, to step Merge: 001F15
- to stream Main, to step Curation: 001F01
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis</title><author><name sortKey="Bernatsky, S" sort="Bernatsky, S" uniqKey="Bernatsky S" first="S." last="Bernatsky">S. Bernatsky</name></author><author><name sortKey="Hudson, M" sort="Hudson, M" uniqKey="Hudson M" first="M." last="Hudson">M. Hudson</name></author><author><name sortKey="Suissa, S" sort="Suissa, S" uniqKey="Suissa S" first="S." last="Suissa">S. Suissa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2B3D475E110E1A8B799BC758757F70306C122CE0</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1093/rheumatology/keh610</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-26W8R0Q2-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000252</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000252</idno><idno type="wicri:Area/Istex/Curation">000252</idno><idno type="wicri:Area/Istex/Checkpoint">000D51</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D51</idno><idno type="wicri:doubleKey">1462-0324:2005:Bernatsky S:anti:rheumatic:drug</idno><idno type="wicri:Area/Main/Merge">001F15</idno><idno type="wicri:Area/Main/Curation">001F01</idno><idno type="wicri:Area/Main/Exploration">001F01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis</title><author><name sortKey="Bernatsky, S" sort="Bernatsky, S" uniqKey="Bernatsky S" first="S." last="Bernatsky">S. Bernatsky</name><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Hudson, M" sort="Hudson, M" uniqKey="Hudson M" first="M." last="Hudson">M. Hudson</name><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Suissa, S" sort="Suissa, S" uniqKey="Suissa S" first="S." last="Suissa">S. Suissa</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Royal Victoria Hospital, McGill University Health Centre, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Rheumatology</title><title level="j" type="abbrev">Rheumatology</title><idno type="ISSN">1462-0324</idno><idno type="eISSN">1462-0332</idno><imprint><publisher>Oxford University Press</publisher><date type="e-published" when="2005-03-22">2005</date><date when="2005-05">2005</date><biblScope unit="vol">44</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="677">677</biblScope><biblScope unit="page" to="680">680</biblScope></imprint><idno type="ISSN">1462-0324</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-0324</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective. To assess the risk of hospitalization for congestive heart failure (CHF) associated with the use of disease-modifying anti-rheumatic drugs (DMARDs) and other medications used in RA. Methods. We used a case–control design nested within an administrative database cohort of patients with rheumatoid arthritis (RA) who were dispensed a DMARD between September 1998 and December 2001. Subjects identified with a prior history of CHF were excluded. For each hospitalized case of CHF identified during follow-up, 10 controls matched on age and time were randomly selected from the cohort. Conditional logistic regression was used to estimate the rate ratio (RR) of hospitalizations for CHF associated with the current use of specific drugs, adjusted for sex and co-morbidity. Results. The cohort included 41 885 patients; 75% were women, with an average age at cohort entry of 51 yr. During follow-up, 520 hospitalizations for CHF occurred, for a rate of 10.1 per 1000 per year. The adjusted RR of CHF for current use of any DMARD was 0.7 (95% CI 0.6–0.9) relative to no current use. By DMARD category, there was evidence of a beneficial effect for both tumour necrosis factor-α antagonists (RR 0.5, 95% CI 0.2–0.9) and methotrexate monotherapy (RR 0.8, 95% CI 0.6–1.0). For non-DMARD medications, the rate of CHF was not clearly increased or decreased, except for COX-2 inhibitors. The data suggested an increased risk of CHF with rofecoxib (RR 1.3, 95% CI 1.0–3.1) and a decreased risk of CHF with celecoxib (RR 0.6, 95% CI 0.4, 1.0). Conclusions. The use of DMARDs was associated with a reduction in the risk of hospitalizations for CHF in this RA cohort. The increased risk with rofecoxib alongside a decreased risk with celecoxib suggests the absence of a class effect with respect to COX-II inhibitors for some types of cardiovascular morbidity.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement></list><tree><noCountry><name sortKey="Bernatsky, S" sort="Bernatsky, S" uniqKey="Bernatsky S" first="S." last="Bernatsky">S. Bernatsky</name><name sortKey="Hudson, M" sort="Hudson, M" uniqKey="Hudson M" first="M." last="Hudson">M. Hudson</name></noCountry><country name="Canada"><region name="Québec"><name sortKey="Suissa, S" sort="Suissa, S" uniqKey="Suissa S" first="S." last="Suissa">S. Suissa</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2B3D475E110E1A8B799BC758757F70306C122CE0
|texte= Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |